In the final episode of Season 5, Keturah Taylor talks with Cozen O’Connor colleagues Danielle Sapega and Rick Van Buren about the complex regulatory environment for GLP-1 drugs—including increasing state AG scrutiny—and they outline a road map to help legitimate market participants avoid pitfalls.